Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.60 |
| ▸ | CTSS | P25774 | 3/20 | 0.60 |
| ▸ | CTSK | P43235 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.51 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.51 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.51 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120554 | 1.00 | CTSL (0.60) | CTSLCTSSCTSKALDH1A1LMNA | |
| SCHEMBL1120555 | 1.00 | CTSL (0.60) | CTSLCTSSCTSKALDH1A1LMNA | |
| SCHEMBL1120503 | 0.99 | CTSL (0.61) | CTSLCTSSCTSKALDH1A1LMNA | |
| SCHEMBL1120500 | 0.99 | CTSL (0.61) | CTSLCTSSCTSKALDH1A1LMNA | |
| SCHEMBL1120498 | 0.99 | CTSL (0.61) | CTSLCTSSCTSKALDH1A1LMNA | |
| SCHEMBL4805645 | 0.97 | LMNA (0.59) | CTSLCTSSCTSKALDH1A1LMNA | |
| SCHEMBL4805638 | 0.97 | LMNA (0.59) | CTSLCTSSCTSKALDH1A1LMNA | |
| SCHEMBL4805654 | 0.97 | LMNA (0.59) | CTSLCTSSCTSKALDH1A1LMNA | |
| SCHEMBL13853940 | 0.93 | CTSL (0.63) | CTSLCTSSCTSKCTSBADORA3 | |
| SCHEMBL1120570 | 0.91 | ADORA1 (0.55) | CTSLCTSSCTSKALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943251-B8 | A1 ADENOSINE RECEPTOR AGONISTS | GILEAD PALO ALTO INC (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-1943251-B1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090137520-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ELZEIN ELFATIH | 2009-05-28 | — | — | US | disclosed |
| US-7488720-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1943251-A2 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7381714-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1883646-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007047401-A2 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070087994-A1 | treating tachycardia and atrial flutter, angina, and myocardial infarction; N-({9-[(4S ,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(cyclopentylamino)purin-2-yl}methyl)carbamoylmethylsulfonic acid | CV THERAPEUTICS, INC. | 2007-04-19 | — | — | US | disclosed |
| US-20060276428-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006125190-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137520-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ADORA1, ADORA2A, ADORA3 | CTSL 4038/4885CTSS 3734/4885CTSK 3749/4885 |
| US-20060276428-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | CTSL 4057/4885CTSS 4237/4885CTSK 4183/4885 |
| US-20070087994-A1 | treating tachycardia and atrial flutter, angina, and myocardial infarction; N-({9-[(4S ,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(cyclopentylamino)purin-2-yl}methyl)carbamoylmethylsulfonic acid | FFAR1, ADORA3, ADORA1 | CTSL 3202/4885CTSS 1956/4885CTSK 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.